Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate

Journal of Rheumatology

Volumn 26, Issue 11, 1999, Pages 2318-2323

  Cantatore, Francesco Paolo ^a,b   Acquista, Carmine Alessandro ^a   Pipitone, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b NONE   (Italy)

Author keywords

Alendronate; Cytokines; Osteoporosis; Rheumatoid arthritis

Indexed keywords

ADRONAT; ALENDRONIC ACID; ANTIRHEUMATIC AGENT; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTHRITIS; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; ALENDRONATE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BETA 2-MICROGLOBULIN; BONE AND BONES; BONE RESORPTION; C-REACTIVE PROTEIN; CYTOKINES; EVALUATION STUDIES; FEMALE; HUMANS; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 0032703282     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hooyman JR, Melton LJ III, Nelson AM, O'Fallon WM, Riggs BL. Fractures after rheumatoid arthritis: a population-based study. Arthritis Rheum 1984;27:1353-61.
2. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral. content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
3. Sambrook PN, Eisman JA, Champion D, Yeates MG, Pocock NA, Eberl S. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 1987;30:721-8.
4. Laan RFJM, van Riel PLCM, van de Putte LBA. Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis 1992;51:826-32.
5. Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991;20:256-72.
6. Gough AKS, Liley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7.
7. Miossec P. Cytokine abnormalities in inflammatory arthritis, new developments in investigation and management of early inflammatory arthritis. P. Emery, editor. London: Bailliere's Clin Rheumatol 1992;6:373-92.
8. Lotz M, Moats T, Villiger PM. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to pathogenesis of arthritis. J Clin Invest 1992;90:888-886.
9. Canalis E, McCarty T, Centrella M. A bone derived growth factor isolated from rat calvariae is beta 2 microglobulin. Endocrinology 1984;121:1198-200.
10. 2 microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis. Ann Rheum Dis 1989;48:905-11.
11. 2 microglobulin induces calcium efflux from cultured neonatal mouse calvariae. Ann J Physiol 1992;263:F540-5.
12. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 1991;42:919-44.
13. Dunn CJ, Galinet LA, Wu H, et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993;226:1691-8.
14. Nakamura M, Ando T, Abe S, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 1996;119:205-12.
15. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metabol 1996;81:961-7.
16. Roodman GD, Kurihara N, Ohsaki Y, et al. Interleukin-6 a potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992;89:46-52.
17. Eggelmeijer F, Papapoulos SE, Westedt ML, van Passen HC, Dijkmans BAC, Breedveld FC. Bone metabolism in rheumatoid arthritis: relation to disease activity. Br J Rheumatol 1993;32:387-91.
18. Tan PL, Ames R, Yeoman S, Ibbertson HK, Caughey DE. Effects of aminobisphosphonate infusion on biochemical indices of bone metabolism in rheumatoid arthritis. Br J Rheumatol 1989;28:325-8.
19. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 1993;95 Suppl 5A:48-51.
20. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Arthritis Rheum 1996;39:396-402.
21. Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphtmates on macrophages. Calcif Tissue Int 1986;38:227-33.
22. Chambers TJ. Diphosphonates inhibit bone resorption by macrophages in vitro. J Pathol 1980;112:255-62.
23. Poulik MD, Bloom AD. Beta 2 microglobulin production and secretion by lymphocytes in culture. J Immunol 1973;110:1430-3.
24. Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979;22:340-6.
25. Barbier A, Breliere JC, Remandet B, Roncucci R. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986;45:67-74.
26. Eggelmeijer F, Papapoulos SE, van Passen HC, Dijkmans BAC, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994;21:2016-20.
27. Maccagno A, Di Giorgio E, Roldan EJ, Caballero LE, Perez-Lloret A. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 1994;23:211-4.